Date: 2015-02-10
Type of information: Financing round
Company: Inoviem Scientific (France)
Investors: Cap Innov’Est (France)
Amount: € 0.5 million
Funding type: financing round
Planned used: Inoviem Scientific is a Contract Research Biotech (CRB) that aims to innovate and develop new technologies for the benefit of its pharmaceutical and biotechnology industry clients, supporting them in developing safer pharmacological agents. The company was founded in 2011 by Dr. Pierre Eftekhari and is rooted in two proprietary technologies that underpin the company. At the end of 2013 Dr. Pierre Eftekhari, chairman, scientific manager and inventor of Inoviem Scientific’s technologies was joined by Dr. Frédéric Perraud, CFO and Dr. Daniel Da Costa, business development manager. In 2013, Inoviem Scientific hired its first employees and moved into premises at the Strasbourg-based Institut de Sciences et d’Ingénierie Supramoléculaire (institute of supramolecular sciences and engineering). The company now has around ten staff. Inoviem Scientific leverages two proprietary technologies to offer the pharmaceutical industry access at all stages of drug development. The company supports all stages of drug development, from drug discovery (identification of primary and secondary targets, detection of potential adverse effects) through to clinical trials (patient stratification, identification of biomarkers, etc.). Its technologies are based on new biophysical analysis techniques. It is one of the first companies in the world to conduct label-free analysis of the interaction between a candidate drug and its target, using human samples directly from patients. This investment of €500,000 ($566,000) will allow Inoviem to put its technologies into production and enter the European market over the next 12 months. The company expects to increase its staffing by 50% in 2015 to support its European expansion plans. At the start of 2015 Inoviem opened an office in Frankfurt, Germany, to grow its business in the German, Austrian and Benelux markets.
Others: * On February 10, 2015, Inoviem Scientific, a Contract Research Biotech (CRB), announced that it raised €500,000 ($566,000) in seed funding with Cap Innov’Est. To consolidate its expansion, Inoviem Scientific approached Cap Innov’Est to raise €500,000 ($566,000). Cap Innov’Est is a seed capital fund for the three French regions of Alsace, Burgundy and Franche-Comté, managed by Alsace Capital in partnership with Invest PME (a subsidiary of private equity group Siparex),
Therapeutic area: Technology - Services
